Lynn Morris to Neutralization Tests
This is a "connection" page, showing publications Lynn Morris has written about Neutralization Tests.
Connection Strength
2,657
-
Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth. Front Immunol. 2021; 12:734110.
Score: 0,185
-
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021 04; 27(4):622-625.
Score: 0,178
-
Antibody Isotype Switching as a Mechanism to Counter HIV Neutralization Escape. Cell Rep. 2020 11 24; 33(8):108430.
Score: 0,175
-
Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. mSphere. 2020 Jan 29; 5(1).
Score: 0,165
-
Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments. J Virol. 2017 10 01; 91(19).
Score: 0,140
-
Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women. AIDS. 2016 Apr 24; 30(7):1005-14.
Score: 0,127
-
Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med. 2012 Nov; 18(11):1688-92.
Score: 0,100
-
Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site. J Virol. 2011 Sep; 85(17):9039-50.
Score: 0,091
-
Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. Virology. 2010 Jun 20; 402(1):187-96.
Score: 0,084
-
Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol. 2009 Nov; 83(21):11265-74.
Score: 0,080
-
Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol. 2009 Sep; 83(17):8925-37.
Score: 0,079
-
International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One. 2009; 4(2):e4505.
Score: 0,077
-
4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response. J Virol. 2008 Mar; 82(5):2367-75.
Score: 0,071
-
N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. J Virol. 2007 Oct; 81(19):10769-76.
Score: 0,069
-
Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med. 2006 Jul; 3(7):e255.
Score: 0,064
-
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol. 2005 Aug; 79(16):10103-7.
Score: 0,060
-
Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission. J Virol. 2022 02 23; 96(4):e0193421.
Score: 0,047
-
Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies. J Virol. 2022 01 26; 96(2):e0164321.
Score: 0,047
-
HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function. Front Immunol. 2021; 12:733958.
Score: 0,046
-
Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). N Engl J Med. 2021 06 03; 384(22):2161-2163.
Score: 0,045
-
Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci Transl Med. 2019 09 18; 11(510).
Score: 0,040
-
Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAb lineage. PLoS Pathog. 2019 09; 15(9):e1008005.
Score: 0,040
-
Plasma IL-5 but Not CXCL13 Correlates With Neutralization Breadth in HIV-Infected Children. Front Immunol. 2019; 10:1497.
Score: 0,040
-
Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage. PLoS Pathog. 2018 01; 14(1):e1006825.
Score: 0,036
-
HIV-1 superinfection can occur in the presence of broadly neutralizing antibodies. Vaccine. 2018 01 25; 36(4):578-586.
Score: 0,036
-
Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Sci Transl Med. 2017 09 06; 9(406).
Score: 0,035
-
Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope. J Virol. 2017 09 15; 91(18).
Score: 0,035
-
Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. Sci Transl Med. 2017 03 15; 9(381).
Score: 0,034
-
Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathog. 2017 01; 13(1):e1006074.
Score: 0,033
-
Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. PLoS Pathog. 2017 01; 13(1):e1006148.
Score: 0,033
-
Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. EBioMedicine. 2016 Oct; 12:196-207.
Score: 0,033
-
HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms. Retrovirology. 2016 08 30; 13(1):60.
Score: 0,033
-
Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat Med. 2015 Nov; 21(11):1332-6.
Score: 0,031
-
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014 May 01; 509(7498):55-62.
Score: 0,027
-
Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science. 2013 May 10; 340(6133):751-6.
Score: 0,026
-
Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. J Virol. 2013 Jul; 87(13):7218-33.
Score: 0,026
-
UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C. J Virol. 2012 May; 86(9):4989-99.
Score: 0,024
-
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol. 2011 Oct; 85(19):9998-10009.
Score: 0,023
-
Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol. 2011 Apr; 85(7):3128-41.
Score: 0,022
-
High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology. 2009 May 10; 387(2):414-26.
Score: 0,019
-
Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. Virology. 2009 Mar 15; 385(2):505-20.
Score: 0,019
-
Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J Virol. 2009 Feb; 83(3):1240-59.
Score: 0,019
-
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol. 2008 Dec; 82(23):11651-68.
Score: 0,019
-
Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol. 2006 Dec; 80(23):11776-90.
Score: 0,016
-
Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol. 2006 Mar; 80(5):2515-28.
Score: 0,016
-
Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol. 2002 Mar; 76(5):2233-44.
Score: 0,012